ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 11| Issue: 5| May 2025|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2025: 8.691 || ISI Value: 1.188

PHARMACOGENOMICS OF ANTIDEPRESSANT THERAPY: IDENTIFYING GENETIC PREDICTORS OF TREATMENT RESPONSE IN DEPRESSION- A REVIEW

Abhiraj B. Amolik[1], Vishal S. Gaikwad[2], Abhijeet R. Rode[3]
[1]*Student, Pratibhatai Pawar College of Pharmacy, Shrirampur*
[2]*Assistant Professor, Pratibhatai Pawar College of Pharmacy, Srirampur*
[3]*Assistant Professor, Prathama Pawar College of Pharmacy, Shrirampur*

ABSTRACT
This review aims to explore the role of pharmacogenomics in predicting and optimizing antidepressant treatment outcomes in patients with Major Depressive Disorder (MDD). A narrative review was conducted, synthesizing findings from clinical trials, genetic studies, and pharmacogenomic platforms. The focus was on genetic polymorphisms influencing antidepressant metabolism (CYP2D6, CYP2C19) and response (SLC6A4, HTR2A, BDNF). Key clinical trials and current commercial pharmacogenomic tools were analyzed to assess efficacy, utility, and limitations. Studies demonstrate that pharmacogenomic-guided therapy can enhance treatment response and reduce adverse effects compared to standard care. Specific genetic variants significantly affect drug metabolism and therapeutic outcomes, suggesting utility in guiding antidepressant selection. However, challenges such as limited predictive power, high costs, and population-specific variability remain barriers to widespread implementation. Pharmacogenomics offers a promising path toward personalized psychiatry by minimizing trial- and-error prescribing. Future integration of multi-omics data and AI-driven tools may further improve its clinical relevance and accessibility.

KEYWORD: *Pharmacogenomics, Major Depressive Disorder (MDD), Antidepressant response, Genetic polymorphisms, CYP2D6 and CYP2C19, SLC6A4 and HTR2A, Personalized psychiatry*

INTRODUCTION
Major Depressive Disorder (MDD) is a prevalent and debilitating psychiatric illness affecting over 280 million people globally. It is characterized by persistent sadness, anhedonia, cognitive impairments, and a significant reduction in quality of life [1]. Despite the wide array of antidepressant medications available ranging from selective serotonin reuptake inhibitors (SSRIs) to serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and atypical agents clinical response remains highly variable [2,3]. Approximately 30– 50% of patients fail to achieve an adequate response to initial pharmacological treatment, and many experience adverse drug reactions that contribute to discontinuation and relapse [4,5,6].




Fig no 1: Variability in Patient Response to the same Antidepressant Treatment.

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 11| Issue: 5| May 2025|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2025: 8.691 || ISI Value: 1.188

This interindividual variability in antidepressant response has prompted growing interest in the field of pharmacogenomics, which investigates how genetic variations influence drug efficacy, metabolism, and safety [7]. By identifying specific genetic markers associated with treatment outcomes, pharmacogenomics aims to guide clinicians in selecting the most appropriate antidepressant for each patient thus moving toward a more precise, personalized approach to psychiatric care [8,9,10]. Over the past two decades, numerous studies have explored the impact of genetic polymorphisms in genes related to drug metabolism (e.g., CYP2D6, CYP2C19), neurotransmitter transport and receptor activity (e.g., SLC6A4, HTR2A), and neuroplasticity (e.g., BDNF) on antidepressant response. Several commercial pharmacogenomic testing platforms have also emerged, offering clinicians decision-support tools based on a patient's genetic profile. This review aims to provide a comprehensive overview of the current evidence surrounding genetic predictors of antidepressant treatment response [11,12]. It also examines the clinical utility of pharmacogenomic testing, highlights existing limitations and challenges, and discusses future directions for integrating genomics into routine psychiatric practice [13].

Major Depressive Disorder (MDD) is a complex, multifactorial psychiatric condition characterized by persistent low mood, loss of interest or pleasure, and a range of cognitive and somatic symptoms. It is a leading cause of disability worldwide, contributing substantially to the global burden of disease. Despite advances in psychopharmacology, the treatment of MDD remains challenging due to the considerable heterogeneity in both symptom presentation and treatment response. Antidepressant medications such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and atypical antidepressants form the cornerstone of pharmacological treatment. However, their efficacy is far from universal [14]. Clinical studies have shown that nearly two-thirds of patients do not achieve full remission with first-line treatment, and up to 30% may be classified as treatment-resistant [15].

This variability in treatment outcomes is influenced by numerous factors, including age, sex, comorbidities, environmental influences, and, increasingly recognized, genetic makeup. Pharmacogenomics, a subfield of precision medicine, focuses on understanding how genetic variations influence an individual's response to drugs. In psychiatry, pharmacogenomics holds great promise in guiding antidepressant selection, dosage adjustments, and risk assessment for adverse drug reactions. This individualized approach has the potential to reduce the current trial- and-error prescribing model, shorten time to response, and improve overall treatment outcomes [16,17].

Several genes have been extensively studied in the context of antidepressant response. These include genes encoding for cytochrome P450 enzymes (e.g., CYP2D6, CYP2C19), which are involved in drug metabolism, as well as genes affecting neurotransmitter transport and receptor activity (e.g., SLC6A4, HTR2A, HTR2C) and neurotrophic signaling (e.g., BDNF). Variants in these genes can significantly alter drug plasma concentrations, therapeutic efficacy, and susceptibility to side effects [18]. As a result, pharmacogenomic testing has gained increasing interest both in clinical research and practice, with several commercial platforms now offering multi-gene panels to inform prescribing decisions [19].

Despite its promise, the clinical implementation of pharmacogenomics in psychiatry faces several challenges. These include limited predictive power of individual genetic markers, variability across ethnic populations, inconsistent findings across studies, and logistical barriers such as cost and lack of standardization. Nevertheless, emerging evidence and growing integration of genomic data into electronic health records suggest that pharmacogenomics is steadily moving toward broader clinical utility [20].

This review aims to synthesize the current state of knowledge regarding the pharmacogenomics of antidepressant therapy. It will explore key genetic variants associated with antidepressant response, assess the validity and utility of existing pharmacogenomic tests, discuss their implications for clinical practice, and highlight future directions for research and integration into precision psychiatry [21].

The development of antidepressants in the mid-20th century marked a significant advancement in the treatment of MDD. However, the efficacy of these treatments has remained limited by interindividual variability in therapeutic response and tolerability. This has led clinicians to rely on a "trial-and-error" approach, which often results in prolonged patient suffering, increased healthcare costs, and a higher risk of suicide during treatment delays [22,23]. The landmark STAR*D (Sequenced Treatment Alternatives to Relieve Depression) trial, the largest clinical study of depression treatment to date, found that only about one-third of patients achieved remission with initial SSRI therapy, and each successive treatment step yielded diminishing returns. These sobering statistics have catalysed interest in pharmacogenomics as a tool to improve treatment precision. Pharmacogenomics differs from broader pharmacogenetics in that it involves the study of multiple genes and their interactions, providing a more holistic view of drug response [24]. The concept is rooted in the recognition that individual genetic variation plays a crucial role in drug absorption, distribution, metabolism, excretion (ADME), and mechanism of action. As applied to antidepressants, pharmacogenomic insights can be leveraged to inform choices such as:

- Which class of antidepressant is most likely to be effective,
- What starting dose is appropriate based on metabolic capacity,
- Which patients are at greater risk of experiencing side effects or adverse reactions.

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 11| Issue: 5| May 2025|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2025: 8.691 || ISI Value: 1.188

One of the most robust and clinically actionable areas of pharmacogenomics involves the cytochrome P450 enzyme family, particularly CYP2D6 and CYP2C19. These enzymes metabolize a majority of antidepressants, and polymorphisms in these genes can lead to poor, intermediate, extensive, or ultra-rapid metabolism. Poor metabolizers may accumulate toxic drug levels, increasing side effect risk, while ultra-rapid metabolizers may clear drugs too quickly to derive therapeutic benefit. Beyond metabolism, polymorphisms in neurotransmitter-related genes such as SLC6A4 (serotonin transporter), HTR2A/HTR2C (serotonin receptors), and BDNF (brain-derived neurotrophic factor) have been associated with altered antidepressant response. These genes are involved in drug-target interactions, neuronal plasticity, and stress response, all of which are relevant to the pathophysiology of depression [15,26, 27].

Commercial pharmacogenomic testing platforms now offer panels that assess multiple pharmacokinetic and pharmacodynamic genes. Tests such as GeneSight®, CNSDose®, and Neuropharmagen® provide clinicians with color-coded or tiered reports categorizing drugs into "use as directed," "use with caution," or "avoid" categories. These tools are increasingly being adopted in psychiatric practice, although their evidence base and cost-effectiveness remain subjects of active investigation. Additionally, the field is rapidly evolving [28]. Recent studies have begun integrating polygenic risk scores (PRS) and applying machine learning algorithms to predict treatment response based on combinations of genetic, clinical, and environmental variables. While these methods are still in development, they represent the next frontier in precision psychiatry. In summary, the integration of pharmacogenomics into antidepressant therapy represents a paradigm shift from empirical prescribing to a more informed, individualized treatment model. As the evidence base grows and technological barriers decline, pharmacogenomics is poised to become a central component of personalized mental health care [29].

Pharmacological therapy represents one of the essential approaches to treatment of Major Depressive Disorder (MDD). However, currently available antidepressant medications show high rates of first-level treatment non-response, and several attempts are often required to find an effective molecule for a specific patient in clinical practice. In this context, pharmacogenetic analyses could represent a valuable tool to identify appropriate pharmacological treatment quickly and more effectively. However, the usefulness and the practical effectiveness of pharmacogenetic testing currently remains an object of scientific debate [1,8,9]. The present narrative and critical review focuses on exploring the available evidence supporting the usefulness of pharmacogenetic testing for the treatment of MDD in clinical practice, highlighting both the points of strength and the limitations of the available studies and of currently used tests. Future research directions and suggestions to improve the quality of available evidence, as well as consideration on the potential use of pharmacogenetic tests in everyday clinical practice are also presented [30].

Major Depressive Disorder (MDD) is a common psychiatric disorder, affecting more than 300 million people globally and representing an important cause of disability worldwide Symptomatic remission and maintenance of therapeutic effects over time are the primary goals of MDD treatment and the most common first-line therapeutic strategy for moderate to severe MDD is pharmacological: although different classes of antidepressants are currently available, the pharmacological approach to this disorder is commonly a process of trial and error, thus, it may (and often does) take several attempts to identify the optimal treatment for an individual patient Approximately one third of patients achieve remission after the first therapeutic trial, whereas about another third develop a treatment-resistant form of depression. The inherent biological and environmental heterogeneity among patients with this disorder could be one of the causes of the high non-response and incomplete remission rates, suggesting the potential usefulness of identifying specific biomarkers able to predict the response to antidepressants and allowing to individually tailor the treatment for each subject Specific guidance for clinicians to navigate which antidepressant is better suited for each patient, therefore, is much needed: pharmacogenetics aims at doing precisely that by combining aspects such as genetic variability, pharmacokinetics, and clinical outcomes, allowing drug selection based on the genomic characteristics of the individual patient [3,32]. In the context of MDD, current evidence focuses on pharmacokinetics, and in particular on the variability of two genes involved in drug metabolism: CYP2C19 and CYP2D6 Other genes have also been identified as biomarkers in the response to antidepressant therapy (e.g., some serotonin's receptors and pathway's molecules like SCL6A4 and HTR2A) and, despite more limited clinical validity and efficacy, have also been included in many commercially available pharmacogenetic test panels Although several randomized controlled trials (RCTs) have yielded interesting results regarding the impact of pharmacogenetic tests on the efficacy outcome of MDD patients' treatment, conflicting opinions remain regarding their usefulness in everyday clinical practice The aim of the present narrative and critical review is to analyse the available literature in order to assess, without neglecting possible criticalities and limitations, the evidence on the efficacy, safety and applicability of currently available pharmacogenetic tests in the context of MDD treatment [33].

The traditional approach to treating depression often involves a trial-and-error method, leading to delayed therapeutic effects and increased risk of adverse reactions. Pharmacogenomics aims to optimize treatment by considering individual genetic variations that influence drug metabolism and response [34,35].

PHARMACOGENOMICS OF ANTIDEPRESSANT THERAPY

Serotonin Transporter Gene (SLC6A4) and Its Role in Antidepressant Response: The serotonin transporter gene (SLC6A4) is a crucial gene involved in the regulation of serotonin levels in the brain. It encodes the serotonin transporter (SERT), a protein responsible for reuptaking serotonin from the synaptic

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 11| Issue: 5| May 2025|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2025: 8.691 || ISI Value: 1.188

cleft back into presynaptic neurons. This reuptake process is essential for regulating serotonin's availability in the brain, which in turn influences mood, anxiety, and other emotional states [36].




Fig no 2: Genetic Predictors in Pharmacogenomics of Antidepressant Therapy.




Fig no 3: Regulation of Serotonin Transporter Gene (5-HTT).

- Structure and Function of SLC6A4: The SLC6A4 gene spans about 28 kb on chromosome 17 and produces the serotonin transporter (SERT) protein. The serotonin transporter facilitates the transport of serotonin (5-HT) across the neuronal membrane, essentially clearing serotonin from the synapse after it has transmitted its

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 11| Issue: 5| May 2025|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2025: 8.691 || ISI Value: 1.188

signal to the postsynaptic neuron [37].

By regulating serotonin levels, SERT plays a central role in mood regulation, and alterations in its function are associated with mood disorders such as depression, anxiety, and obsessive-compulsive disorder (OCD) [38].

Key Polymorphisms: 5-HTTLPR and Its Impact One of the most studied polymorphisms in the SLC6A4 gene is the 5-HTTLPR (serotonin-transporter-linked polymorphic region), which is located in the promoter region of the gene. This polymorphism is characterized by two main alleles: a long (L) allele and a short (S) allele.

- 5-HTTLPR Polymorphism: Long (L) Allele: The long allele results in higher transcriptional activity, leading to greater expression of the serotonin transporter (SERT). This means more serotonin is taken back up into the presynaptic neuron.
- Short (S) Allele: The short allele is associated with lower transcriptional activity and reduced expression of SERT. This leads to less serotonin reuptake, potentially resulting in higher serotonin levels in the synapse [39, 40].
- Effects of the 5-HTTLPR Polymorphism on Antidepressant Response

a) Response to Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs, such as fluoxetine (Prozac) and sertraline (Zoloft), work by inhibiting the serotonin transporter, thus increasing the availability of serotonin in the synaptic cleft. The response to SSRIs can be influenced by the 5-HTTLPR polymorphism.L allele (high expression of SERT): Individuals with the long allele tend to have a better response to SSRIs, possibly because the inhibition of serotonin reuptake by SSRIs further enhances serotonin levels in the synapse.S allele (low expression of SERT): Individuals with the short allele may have a reduced response to SSRIs, possibly due to already elevated serotonin levels in the synaptic cleft, making additional serotonin reuptake inhibition less effective. These individuals may also experience more side effects from SSRIs.

b) Stress Sensitivity and Depression Risk: People carrying the S/S genotype (two short alleles) may exhibit greater susceptibility to stress and a higher risk for developing depression. This is because the short allele is associated with a more reactive serotonin transporter system, which could make these individuals more vulnerable to environmental stressors. Studies have shown that people with the S/S genotype exhibit altered serotonin regulation, making them more prone to emotional dysregulation and mood disorders, particularly under stressful conditions[41,2,43,44].

1) **Cytochrome P450 Enzymes (CYP450):** An Overview in Antidepressant Therapy: The cytochrome P450 (CYP450) enzyme system is a group of enzymes primarily found in the liver that play a major role in the metabolism of drugs, including many antidepressants. Genetic variations in these enzymes can significantly affect how individuals metabolize medications, influencing drug efficacy, toxicity, and side effects.




Fig no 4: Phases of Xenobiotic Metabolism and Detoxification Pathways Key CYP450 Enzymes Involved in Antidepressant Metabolism

- CYP2D6

Metabolizes: SSRIs (fluoxetine, paroxetine), tricyclic antidepressants (TCAs), and others.

Genetic Variants: Poor metabolizers: Reduced or no enzyme activity → drug builds up → increased risk of side effects.

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 11| Issue: 5| May 2025|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2025: 8.691 || ISI Value: 1.188

Ultra-rapid metabolizers: Excess enzyme activity → drug cleared too fast → reduced therapeutic effect.

- CYP2C19
  Metabolizes: SSRIs (citalopram, escitalopram, sertraline), TCAs.
  Genetic Variants: Poor metabolizers: Risk of higher plasma drug levels, leading to side effects.
  Rapid/Ultra-rapid metabolizers: Reduced drug levels, potentially causing treatment failure.
- CYP3A4 and CYP3A5
  Metabolizes: Venlafaxine, mirtazapine, trazodone.
  These enzymes have less variation between individuals than CYP2D6 or CYP2C19, but interactions with other drugs or dietary substances (like grapefruit) can inhibit or induce their activity.
- CYP1A2
  Metabolizes: Duloxetine, clomipramine. Activity can be induced by smoking, leading to faster drug clearance and potentially lower effectiveness [45,46, 47].

Clinical Implications of CYP450 Variants

- Personalizing Antidepressant Selection: Genetic testing can identify if a patient is a poor, intermediate, extensive, or ultra-rapid metabolizer.
  For example: CYP2D6 poor metabolizer → avoid paroxetine due to increased risk of side effects.
  CYP2C19 ultra-rapid metabolizer → consider alternatives to escitalopram due to reduced effectiveness.
- Dose Adjustments: Knowing a patient's CYP450 genotype helps in adjusting the dose to reach therapeutic levels safely.
- Avoiding Drug Interactions: Co-administration of drugs that inhibit or induce CYP enzymes can affect antidepressant levels. For instance: Fluoxetine inhibits CYP2D6, potentially increasing levels of co-administered CYP2D6 substrates.

Pharmacogenomic Testing Tools: Commercial tests like GeneSight, NexGen, and IDgenetix analyze CYP450 genes among others, helping clinicians personalize antidepressant therapy based on genetic profiles [48,49,50,51].

2) **Brain-Derived Neurotrophic Factor (BDNF):** Brain-Derived Neurotrophic Factor (BDNF) is a protein that belongs to the neurotrophin family, which also includes nerve growth factor (NGF). BDNF is vital for the development, maintenance, and plasticity of neurons in the central nervous system (CNS) [52].




Fig no 5: Role of BDNF/TrkB Signalling in Neurodegenerative and Psychiatric Disorders and Therapeutic Effects of BDNF Mimetics.

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 11| Issue: 5| May 2025|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2025: 8.691 || ISI Value: 1.188

Main Functions of BDNF

- Neuronal Survival: Prevents programmed cell death (apoptosis) and supports existing neurons.
- Neurogenesis: Stimulates the growth of new neurons, especially in the hippocampus-a brain region important for memory and emotion.
- Synaptic Plasticity: Enhances the strength and number of synaptic connections, crucial for learning and memory.
- Stress Adaptation: Helps the brain adapt to stress by remodeling neural circuits [53,54, 55].

- BDNF and the Brain: High concentrations are found in the hippocampus, amygdala, cerebral cortex, and hypothalamus. These areas regulate emotion, cognition, stress response, and mood, linking BDNF directly to mental health.
- BDNF and Depression: Depressed patients often show low levels of BDNF, especially in the hippocampus. Chronic stress suppresses BDNF expression, leading to neuron shrinkage and hippocampal atrophy. Recovery from depression is associated with restoration of BDNF levels.
- BDNF and Antidepressant Action: Antidepressants (SSRIs, SNRIs, TCAs) stimulate the production of BDNF. Increased BDNF promotes synaptic repair and neurogenesis, improving mood and cognitive function over time. Ketamine, a rapid-acting antidepressant, also increases BDNF quickly and strongly.
- Clinical Importance:
  - BDNF is a biomarker for depression and a potential target for new antidepressant therapies.
  - The Val66Met genotype can help predict treatment response and personalize psychiatric care [56,57,58].

3) SEROTONIN RECEPTORS

Serotonin receptors, also called 5-hydroxytryptamine (5-HT) receptors, are a group of G protein- coupled receptors (GPCRs) and ligand-gated ion channels that mediate the effects of serotonin, a key neurotransmitter in the central nervous system (CNS).

Here's a detailed explanation of the types of serotonins (5-HT) receptors, focusing on their structure, function, and relevance to antidepressant therapy:




Fig no 6: 5-HT2C Receptor Signalling Pathways and Downstream Effectors.

Types of Serotonin Receptors (5-HT Receptors): There are seven main families of serotonin receptors: 5-HT1 to 5-HT7, with several subtypes. They are mostly G-protein-coupled receptors (GPCRs), except for 5-HT3, which is a ligand-gated ion channel [59,60, 61].




Fig no 7: Classification and Signalling Mechanisms of Serotonin (5-HT) Receptor Subtypes.

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 11| Issue: 5| May 2025|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2025: 8.691 || ISI Value: 1.188

a) 5-HT1 Family (GPCR)
   - Subtypes: 5-HT1A, 1B, 1D, 1E, 1F
   - Location: Raphe nuclei, cortex, hippocampus
   - Function: Inhibits adenylate cyclase → reduces cAMP → inhibitory effect on neurotransmission
   - Role in Mood: 5-HT1A: Key target in depression and anxiety; modulates serotonin release Target of SSRIs and partial agonists (e.g., buspirone)

b) 5-HT2 Family (GPCR)
   - Subtypes: 5-HT2A, 2B, 2C
   - Location: Cortex, hypothalamus, limbic system
   - Function: Activates phospholipase C → increases IP3 and DAG → excitatory effects
   - Clinical Role: 5-HT2A: Atypical antipsychotics block it; associated with antidepressant response and sleep regulation 5-HT2C: Influences appetite, weight gain, and mood regulation

c) 5-HT3 Family (Ion Channel)
   - Only Subtype: 5-HT3
   - Location: Brainstem, GI tract
   - Function: Fast excitatory neurotransmission via ion flow
   - Clinical Relevance: Involved in nausea, especially SSRI-induced Antagonists like ondansetron used to manage these side effects

d) 5-HT4 Family (GPCR)
   - Function: Stimulates adenylate cyclase → increases cAMP
   - Location: GI tract, CNS
   - Role in Depression: Modulates memory and cognition; under investigation as an antidepressant target

e) 5-HT5 Family (GPCR)
   - Subtypes: 5-HT5A (5-HT5B is non-functional in humans)
   - Function: Inhibitory; role still unclea
   - Location: Cortex, hippocampus
   - Potential Role: May regulate circadian rhythm and memory

f) 5-HT6 Family (GPCR)
   - Location: CNS, particularly striatum and cortex
   - Function: Involved in cognition and learning
   - Antidepressant Potential: Being explored as a target in cognitive symptoms of depression

g) 5-HT7 Family (GPCR)
   - Function: Stimulates adenylate cyclase → increases cAMP
   - Location: Thalamus, hypothalamus, hippocampus
   - Role: Circadian rhythm, mood regulation
   - Clinical Potential: 5-HT7 antagonists show promise in rapid antidepressant effects [40,62,63,64,65].

CLINICAL UTILITY OF PHARMACOGENOMIC TESTING

The integration of pharmacogenomic testing into clinical practice has become an increasingly relevant strategy in optimizing antidepressant therapy. Its primary goal is to enhance treatment outcomes by providing prescribers with actionable genetic insights that inform drug selection and dosing. Several pharmacogenomic testing panels—such as GeneSight®, CNSDose®, Neuropharmagen®, and IDgenetix®—are currently available and offer recommendations based on a patient's genetic profile. These tests typically analyze a combination of pharmacokinetic (e.g., CYP2D6, CYP2C19) and pharmacodynamic (e.g., SLC6A4, HTR2A, BDNF) gene variants.

1. Enhancing Treatment Response and Remission Rates: Multiple studies have demonstrated that pharmacogenomic-guided treatment can improve clinical outcomes. Randomized controlled trials (RCTs), such as the GUIDED trial and the GENEPSI study, have shown that patients receiving pharmacogenomic-informed therapy were more likely to achieve symptom improvement and remission compared to those receiving standard care. Notably, patients with genetic variants predicting poor metabolism or adverse effects experienced fewer side effects and higher tolerability when genetic results were used to guide prescribing [66,67].
2. Reducing Trial-and-Error Prescribing:
   Traditional antidepressant prescribing often involves trying multiple medications sequentially over weeks or months. Pharmacogenomic testing helps reduce this trial-and- error process by identifying medications that are more likely to be effective or poorly tolerated based on a patient's genetic profile. This approach can reduce treatment delays, patient frustration, and healthcare utilization [68,69].
3. Cost-Effectiveness:
   Economic analyses suggest that pharmacogenomic-guided treatment may be cost- effective in the long term by decreasing the number of failed medication trials, reducing adverse events, and minimizing hospitalizations. However, the upfront cost of testing remains a barrier in some healthcare systems, and insurance coverage varies widely by region and provider [70].
4. Limitations and Challenges: Despite its promise, pharmacogenomic testing is not without limitations. Many antidepressants are metabolized by multiple enzymes, and gene-drug interactions are often influenced by non-genetic factors such as age, comorbidities, and polypharmacy. Moreover, the predictive power of current genetic panels is modest, and findings may not always be generalizable across diverse populations due to ethnic differences in allele frequencies. Another challenge is the lack of

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 11| Issue: 5| May 2025|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2025: 8.691 || ISI Value: 1.188

standardization among commercial tests, leading to variations in interpretation and reporting. Clinician knowledge and confidence in using pharmacogenomic data also vary, emphasizing the need for greater education and clinical decision support tools [71, 72,73].

5. Regulatory and Guideline Support
   The U.S. Food and Drug Administration (FDA) has provided guidance on the clinical relevance of specific pharmacogenomic markers for certain drugs. Moreover, organizations such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) have developed gene-drug interaction guidelines that support evidence-based implementation of pharmacogenomics in psychiatry [74,75,76].

FUTURE DIRECTIONS

Pharmacogenomics has already begun to reshape the landscape of psychiatric treatment, yet its full potential remains untapped. As research advances and technologies evolve, several key areas are poised to further enhance the precision, accessibility, and clinical impact of pharmacogenomic-guided antidepressant therapy [77,78, 79].

1. Integration of Polygenic Risk Scores (PRS): Current pharmacogenomic tests focus primarily on a limited number of well-characterized single nucleotide polymorphisms (SNPs). However, depression and treatment response are polygenic traits influenced by many small-effect variants. Polygenic risk scores (PRS), which aggregate the effects of hundreds to thousands of genetic variants, offer a more comprehensive view of individual risk and treatment potential. When combined with clinical factors, PRS may significantly improve predictive accuracy for treatment outcomes.
2. Multi-Omics Approaches: Future strategies will likely integrate pharmacogenomics with other "omics" layers—such as transcriptomics, epigenomics, proteomics, and metabolomics—to generate a more complete biological profile of the patient. This systems biology approach may help identify novel biomarkers, therapeutic targets, and response pathways, paving the way for a more nuanced and personalized form of depression treatment.
3. Artificial Intelligence and Machine Learning: The growing availability of high- dimensional genomic and clinical data necessitates the use of advanced computational tools. Machine learning and artificial intelligence (AI) algorithms can be trained on large datasets to uncover complex gene-drug-environment interactions and generate predictive models with higher accuracy than traditional methods. These models may eventually be integrated into electronic health records to provide real-time, automated prescribing recommendations.
4. Population Diversity and Inclusivity: Most pharmacogenomic research to date has been conducted in populations of European descent, limiting generalizability across diverse ethnic groups. Future studies must prioritize the inclusion of underrepresented populations to ensure the equity and accuracy of pharmacogenomic tools. Global consortia and biobanks are increasingly focusing on collecting diverse datasets to address this gap.
5. Digital Health and Point-of-Care Testing: The future of pharmacogenomics may include portable or point-of-care genetic testing devices that allow for immediate analysis and interpretation in clinical settings. Coupled with mobile health applications and digital adherence tools, this could empower patients and clinicians with on-demand, actionable information to guide treatment choices.
6. Policy, Ethics, and Education:
   Wider implementation of pharmacogenomics will also require supportive health policies, regulatory frameworks, and ethical considerations, particularly around data privacy and informed consent. Additionally, increasing clinician education and training in pharmacogenomics is essential to ensure responsible and effective use of genetic information in psychiatric practice.

CONCLUSION

The evolving field of pharmacogenomics offers a transformative approach to managing Major Depressive Disorder (MDD), addressing one of psychiatry's most pressing challenges: the variability in antidepressant response. Despite the broad array of pharmacological treatments available, a significant proportion of patients up to two-thirds fail to achieve full remission with first-line antidepressants. This has traditionally necessitated a trial-and-error approach that is both time-consuming and distressing for patients. Pharmacogenomics, by elucidating the genetic underpinnings of drug response, presents a compelling alternative. Evidence increasingly supports the role of specific genetic variants particularly in genes such as CYP2D6, CYP2C19, SLC6A4, HTR2A, and BDNF in influencing antidepressant metabolism, efficacy, and side effect profiles. Pharmacogenomic testing platforms that incorporate these genes are now available to clinicians, providing actionable insights that can guide antidepressant selection and dosing. Studies have demonstrated that pharmacogenomic-guided treatment can enhance therapeutic outcomes, reduce adverse drug reactions, and shorten the path to remission.

However, challenges remain in translating this promise into routine clinical practice. Variability in genetic expression across populations, limited predictive power of current tests, cost considerations, and the need for clinician education all represent hurdles that must be addressed. Furthermore, a broader integration of polygenic risk scores, multi-omics data, and artificial intelligence holds future potential to refine and enhance the predictive accuracy of pharmacogenomic tools.

REFERENCES

1. *Weinshilboum R. Inheritance and drug response. N Engl J Med. 2003;348:529–37.*
2. *Roden DM, George AL Jr. The genetic basis of variability indrug responses. Nat Rev Drug Discov. 2002;1:37–44.*

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 11| Issue: 5| May 2025|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2025: 8.691 || ISI Value: 1.188

3. *Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC,Baldwin J, et al. Initial sequencing and analysis of the humangenome. Nature. 2001;409:860–921.*
4. *Venter JC, Adams MD, Myers EW, Li PW, Mural RJ,Sutton GG, et al. The sequence of the human genome.Science. 2001;291:1304–51.*
5. *Pare C, Rees L, Saisbury M. Differentiation of twogenetically specific types of depression by the response toantidepressants. Lancet. 1962;29:1340–3.*
6. *Angst J. A clinical analysis of the effects of tofranil indepression: longitudinal and follow-up studies. Treatment ofblood-relations. Psychopharmacologia. 1961;2:381–407.*
7. *O'Reilly RL, Bogue L, Singh SM. Pharmacogeneticresponse to antidepressants in a multicase family withaffective disorder. Biol Psychiatry. 1994;36:467–71.*
8. *Franchini L, Serretti A, Gasperini M, Smeraldi E. Familialconcordance of fluvoxamine response as a tool for differ-entiating mood disorder pedigrees. J Psychiatr Res.1998;32:255–9.*
9. *Turecki G, Grof P, Grof E, D'Souza V, Lebuis L,Marineau C, et al. Mapping susceptibility genes for bipolardisorder: a pharmacogenetic approach based on excellentresponse to lithium. Mol Psychiatry. 2001;6:570–8.*
10. *Serretti A, Franchini L, Gasperini M, Rampoldi R,Smeraldi E. Mode of inheritance in mood disorder familiesaccording to fluvoxamine response. Acta Psychiatr Scand.1998;98:443–50.*
11. *Staddon S, Arranz J, Mancama D, Mata I, Kerwin RW.Clinical application of pharmacogenetics in psychiatry.Psychopharmacology. 2002;162:18–23. Epub 2002Apr 25.*
12. *Steimer W, Muller B, Leucht S, Kissling W.Pharmacogenetics: a new diagnostic tool in the managementof antidepressive drug therapy. Clin Chim Acta.2001;308:33–41.*
13. *Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A. Moleculargenetics of CYP2D6: clinical relevance with focus onpsychotropic drugs. Br J Clin Pharmacol. 2002;53:111–22.*
14. *Nebert DW, Dieter MZ. The evolution of drug metabolism.Pharmacology. 2000;61:124– 35.*
15. *Dalen P, Dahl ML, Ruiz ML, Nordin J, Bertilsson L. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2,3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther.1998;63:444–52.*
16. *Sindrup SH, Brosen K, Gram LF, Hallas J, Skjelbo E,Allen A, et al. The relationship between paroxetine and thesparteine oxidation polymorphism. Clin Pharmacol Ther.1992;51:278–87.*
17. *Ozdemir V, Tyndale RF, Reed K, Herrmann N, Sellers EM,Kalow W, et al. Paroxetine steady-state plasmaconcentration in relation to CYP2D6 genotype inextensive metabolizers. J Clin Psychopharmacol. 1999;19:472–5.*
18. *Veefkind AH, Haffmans PM, Hoencamp E. Venlafaxineserum levels and CYP2D6 genotype. Ther Drug Monit.2000;22:202–8.*
19. *Fukuda T, Nishida Y, Zhou Q, Yamamoto I, Kondo S,Azuma J. The impact of the CYP2D6 and CYP2C19genotypes on venlafaxine pharmacokinetics in a Japanesepopulation. Eur J Clin Pharmacol. 2000;56:175–80.*
20. *Lessard E, Yessine MA, Hamelin BA, O'Hara G, LeBlanc J,Turgeon J. Influence of CYP2D6 activity on thedisposition and cardiovascular toxicity of the antidepres-sant agent venlafaxine in humans. Pharmacogenetics.1999;9:435–43.*
21. *Burke MJ, Preskorn SH. Therapeutic drug monitoring ofantidepressants: cost implications and relevance to clinicalpractice. Clin Pharmacokinet. 1999;37:147–65.22.*
22. *Preskorn SH, Dorey RC, Jerkovich GS. Therapeutic drugmonitoring of tricyclic antidepressants. Clin Chem.1988;34:822–8.*
23. *Preskorn SH, Lane RM. Sertraline 50 mg daily: the optimaldose in the treatment of depression. Int ClinPsychopharmacol. 1995;10:129–41.*
24. *Corruble E, Guelfi JD. Does increasing dose improveefficacy in patients with poor antidepressant response: areview. Acta Psychiatr Scand. 2000;101:343–8.*
25. *Kirchheiner J, Brosen K, Dahl ML, Gram LF, Kasper S,Roots I, et al. CYP2D6 and CYP2C19 genotype-based doserecommendations for antidepressants: a first step towardssubpopulation-specific dosages. Acta Psychiatr Scand.2001;104:173–92.*
26. *Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J,Roots I, et al. Pharmacogenetics of antidepressants andantipsychotics: the contribution of allelic variations to thephenotype of drug response. Mol Psychiatry.2004;9:442–73.*
27. *Brosen K, Naranjo CA. Review of pharmacokinetic andpharmacodynamic interaction studies with citalopram. EurNeuropsychopharmacol. 2001;11:275–83.*
28. *Murphy GM Jr, Kremer C, Rodrigues HE, Schatzberg AF.Pharmacogenetics of antidepressant medication intolerance.Am J Psychiatry. 2003;160:1830–5.*
29. *Brosen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF.Inhibition by paroxetine of desipramine metabolism inextensive but not in poor metabolizers of sparteine.Eur J Clin Pharmacol. 1993;44:349–55.*
30. *Thiebaut F, Tsuruo T, Hamada H, Gottesman MM,Pastan I, Willingham MC. Cellular localization of themultidrug-resistance gene product P-glycoprotein innormal human tissues. Proc Natl Acad Sci U S A.1987;84:7735–8.*
31. *Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L,Biedler JL, Melamed MR, et al. Multidrug-resistance gene(P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A.1989;86:695–8.*
32. *Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences thebrain penetration and pharmacological activity of manydrugs. J Clin Invest. 1996;97:2517–24.*
33. *Uhr M, Steckler T, Yassouridis A, Holsboer F. Penetrationof amitriptyline, but not of fluoxetine, into brain is enhancedin mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology.2000;22:380–7.*
34. *Uhr M, Grauer MT. abcb1ab P-glycoprotein is involved inthe uptake of citalopram and trimipramine into the brain ofmice. J Psychiatr Res. 2003;37:179–85.*
35. *Uhr M, Grauer MT, Holsboer F. Differential enhancementof antidepressant penetration into the brain in mice withabcb1ab*

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 11| Issue: 5| May 2025|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2025: 8.691 || ISI Value: 1.188

(mdr1ab) P-glycoprotein gene disruption. BiolPsychiatry. 2003;54:840–6.

36. *Brinkmann U, Roots I, Eichelbaum M. Pharmacogenetics ofthe human drug-transporter gene MDR1: impact of polymorphisms on pharmacotherapy. Drug Discov Today.2001;6:835–9.*
37. *Uhr M. ABCB1 genotyping is crucial for treatment withdrugs that are P-glycoprotein substrates. Abstract, MeetingSociety of Biological Psychiatry. 2005;57:785.38.*
38. *Ramamoorthy S, Leibach FH, Mahesh VB, Ganapathy V.Partial purification and characterization of the humanplacental serotonin transporter. Placenta. 1993;14:449–61.*
39. *Lesch KP, Wolozin BL, Estler HC, Murphy DL, Riederer P.Isolation of a cDNA encoding the human brain serotonintransporter. J Neural Transm Gen Sect. 1993;91:67–72.*
40. *Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD,Petri S, et al. Association of anxiety-related traits with apolymorphism in the serotonin transporter gene regulatoryregion. Science. 1996;274:1527–31.*
41. *Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D,et al. Allelic variation of human serotonin transporter geneexpression. J Neurochem. 1996;66:2621–4.*
42. *Gelernter J, Cubells JF, Kidd JR, Pakstis AJ, Kidd KK.Population studies of polymorphisms of the serotonintransporter protein gene. Am J Med Genet. 1999;88:61–6.*
43. *Nakamura M, Ueno S, Sano A, Tanabe H. The humanserotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. MolPsychiatry. 2000;5:32– 8.*
44. *Hahn MK, Blakely RD. Monoamine transporter genestructure and polymorphisms in relation to psychiatric andother complex disorders. Pharmacogenomics J.2002;2:217–35.*
45. *Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J,Catalano M. Polymorphism within the promoter of theserotonin transporter gene and antidepressant efficacy offluvoxamine. Mol Psychiatry. 1998;3:508–11.*
46. *Zanardi R, Benedetti F, Di Bella D, Catalano M,Smeraldi E. Efficacy of paroxetine in depression is influ-enced by a functional polymorphism within the promoter ofthe serotonin transporter gene. J Clin Psychopharmacol.2000;20:105–7.*
47. *Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S,Miller M, Sweet RA, et al. Allelic variation in the serotonintransporter promoter affects onset of paroxetine treatmentresponse in late-life depression. Neuropsychopharmacology.2000;23:587–90.*
48. *Arias B, Catalan R, Gasto C, Gutierrez B, Fananas L. 5-HTTLPR polymorphism of the serotonin transporter genepredicts nonremission in major depression patients treatedwith citalopram in a 12-weeks follow up study. J ClinPsychopharmacol. 2003;23:563–7.*
49. *Zanardi R, Serretti A, Rossini D, Franchini L, Cusin C,Lattuada E, et al. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR indelusional and nondelusional depression. Biol Psychiatry.2001;50:323–30.*
50. *Rausch JL, Johnson ME, Fei YJ, Li JQ, Shendarkar N,Hobby HM, et al. Initial conditions of serotonin transporterkinetics and genotype: influence on SSRI treatment trialoutcome. Biol Psychiatry. 2001;51:723–32.*
51. *Joyce PR, Mulder RT, Luty SE, McKenzie JM, Miller AL,Rogers GR, et al. Age- dependent antidepressant pharmaco-genomics: polymorphisms of the serotonin transporter andG protein beta3 subunit as predictors of response tofluoxetine and nortriptyline. Int J Neuropsychopharmacol.2003;6:339–46.*
52. *Durham LK, Webb SM, Milos PM, Clary CM,Seymour AB. The serotonin transporter polymorphism,5HTTLPR, is associated with a faster response time tosertraline in an elderly population with major depressivedisorder. Psychopharmacology (Berl). 2004;174:525–9,Epub 2003 Sep 4.*
53. *Murphy GM Jr, Hollander SB, Rodrigues HE, Kremer C,Schatzberg AF. Effects of the serotonin transporter genepromoter polymorphism on mirtazapine and paroxetineefficacy and adverse events in geriatric major depression.Arch Gen Psychiatry. 2004;61:1163–9.*
54. *Serretti A, Cusin C, Rossini D, Artioli P, Dotoli D,Zanardi R. Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders.Am J Med Genet B Neuropsychiatr Genet. 2004;129:36–40.*
55. *Kim DK, Lim SW, Lee S, Sohn SE, Kim S, Hahn CG, et al.Serotonin transporter gene polymorphism and antidepressant response. Neuroreport. 2000;11:215–9.*
56. *Ito K, Yoshida K, Sato K, Takahashi H, Kamata M,Higuchi H, et al. A variable number of tandem repeats in theserotonin transporter gene does not affect the antidepressantresponse to fluvoxamine. Psychiatry Res. 2002;111:235–9.*
57. *Yoshida K, Ito K, Sato K, Takahashi H, Kamata M,Higuchi H, et al. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response tofluvoxamine in Japanese depressed patients. ProgNeuropsychopharmacol Biol Psychiatry. 2002;26:383–6.*
58. *Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ. Associationstudy of the serotonin transporter promoter polymorphismand symptomatology and antidepressant response in majordepressive disorders. Mol Psychiatry. 2002;7:1115–9.*
59. *Lee MS, Lee HY, Lee HJ, Ryu SH. Serotonin transporterpromoter gene polymorphism and long-term outcome ofantidepressant treatment. Psychiatr Genet. 2004;14:111–5.*
60. *Kato M, Ikenaga Y, Wakeno M, Okugawa G, Nobuhara K,Fukuda T, et al. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. Int Clin Psychopharmacol.2005;20:151–6.*
61. *Minov C, Baghai TC, Schule C, Zwanzger P, Schwarz MJ,Zill P, et al. Serotonin-2A- receptor and -transporter polymorphisms: lack of association in patients with majordepression. Neurosci Lett. 2001;303:119–22.*
62. *Benedetti F, Serretti A, Colombo C, Campori E, Barbini B,di Bella D, et al. Influence of a functional polymorphismwithin the promoter of the serotonin transporter gene on theeffects of total sleep deprivation in bipolar depression.Am J Psychiatry. 1999;156:1450–2.*
63. *Benedetti F, Colombo C, Serretti A, Lorenzi C, Pontiggia A,Barbini B, et al. Antidepressant effects of light*

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 11| Issue: 5| May 2025|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2025: 8.691 || ISI Value: 1.188

therapycombined with sleep deprivation are influenced by afunctional polymorphism within the promoter of theserotonin transporter gene. Biol Psychiatry.2003;54:687–92.

64. *Baghai TC, Schule C, Zwanzger P, Zill P, Ella R, Eser D,et al. No influence of a functional polymorphism within theserotonin transporter gene on partial sleep deprivation inmajor depression. World J Biol Psychiatry. 2003;4:111–4.*
65. *Gardner JP, Fornal CA, Jacobs BL. Effects of sleepdeprivation on serotonergic neuronal activity in the dorsal raphe nucleus of the freely moving cat.Neuropsychopharmacology. 1997;17:72–81.*
66. *Peters EJ, Slager SL, McGrath PJ, Knowles JA,Hamilton SP. Investigation of serotonin- related genes inantidepressant response. Mol Psychiatry. 2004;9:879–89.*
67. *Kraft JB, Slager SL, McGrath PJ, Knowles JA, Hamilton SP.Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol Psychiatry.2005;58:374–81.*
68. *Hu X, Oroszi G, Chun J, Smith TL, Goldman D,Schuckit MA. An expanded evaluation of the relationshipof four alleles to the level of response to alcohol and thealcoholism risk. Alcohol Clin Exp Res. 2005;29:8–16.*
69. *Serretti A. Pharmacogenetics of antidepressants. ClinicalNeuropsychiatry. 2004;1:79–90.*
70. *Lee HJ, Cha JH, Ham BJ, Han CS, Kim YK, Lee SH, et al.Association between a G- protein beta 3 subunit genepolymorphism and the symptomatology and treatmentresponses of major depressive disorders.Pharmacogenomics J. 2004;4:29–33.*
71. *Serretti A, Lorenzi C, Cusin C, Zanardi R, Lattuada E,Rossini D, et al. SSRIs antidepressant activity is influencedby G beta 3 variants. Eur Neuropsychopharmacol.2003;13:117–22.*
72. *Zill P, Baghai TC, Zwanzger P, Schule C, Minov C,Riedel M, et al. Evidence for an association between a G-protein beta3-gene variant with depression and response toantidepressant treatment. Neuroreport. 2000;11:1893–7.*
73. *Serretti A, Zanardi R, Cusin C, Rossini D, Lorenzi C,Smeraldi E. Tryptophan hydroxylase gene associated withparoxetine antidepressant activity. EurNeuropsychopharmacol. 2001;11:375–80.*
74. *Serretti A, Zanardi R, Rossini D, Cusin C, Lilli R,Smeraldi E. Influence of tryptophan hydroxylase andserotonin transporter genes on fluvoxamine antidepressantactivity. Mol Psychiatry. 2001;6:586–92.*
75. *Yoshida K, Naito S, Takahashi H, Sato K, Ito K, Kamata M,et al. Monoamine oxidase: A gene polymorphism, trypto-phan hydroxylase gene polymorphism and antidepressantresponse to fluvoxamine in Japanese patients with majordepressive disorder. Prog Neuropsychopharmacol BiolPsychiatry. 2002;26:1279–83.*
76. *Muller DJ, Schulze TG, Macciardi F, Ohlraun S,Gross MM, Scherk H, et al. Moclobemide response indepressed patients: association study with a functionalpolymorphism in the monoamine oxidase A promoter.Pharmacopsychiatry. 2002;35:157–8.*
77. *Cusin C, Serretti A, Zanardi R, Lattuada E, Rossini D,Lilli R, et al. Influence of monoamine oxidase Aand serotonin receptor 2A polymorphisms in SSRI anti-depressant activity. Int J Neuropsychopharmacol.2002;5:27–35.*
78. *Sato K, Yoshida K, Takahashi H, Ito K, Kamata M,Higuchi H, et al. Association between -1438G/A promoterpolymorphism in the 5-HT(2A) receptor gene and fluvox-amine response in Japanese patients with major depressivedisorder. Neuropsychobiology. 2002;46:136–40.*
79. *Wu WH, Huo SJ, Cheng CY, Hong CJ, Tsai SJ. Associationstudy of the 5-HT(6) receptor polymorphism (C267T) andsymptomatology and antidepressant response in majordepressive disorders. Neuropsychobiology. 2001;44:172–5*